OTOF and deafness: Remarkably, proof‐of‐concept has been established in mouse models of DFNB9, a congenital form of deafness caused by OTOF mutations, and clinical trials for DFNB9 gene therapy have already confirmed the therapeutic potential of this approach for genetic forms of human hearing loss.10, 11, 12, 13, 14, 15